The coronavirus supplemental appropriations bill (H.R. 6379) introduced in the House on 23 March would increase both US pharmaceutical manufacturing capacity and scrutiny of foreign pharmaceutical supply chain risks, reflecting growing concerns among US legislators about foreign dependence, particularly on China.
COVID-19 Vaccines, Therapies Would Get Billion-Dollar Manufacturing Platform Under House Bill
House coronavirus legislation would boost domestic manufacturing capacity while further scrutinizing global supply chain.
More from Legislation
More from Pink Sheet
• By
Most, if not all, adcomm support staff in the drug and biologic centers who handled meeting-specific tasks have been laid off, although sponsors still are preparing for the public reviews. Meanwhile, some cut FDA employees are being called back to work for "continuity of operations activities."
• By
Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.
• By
Pink Sheet reporter and editors discuss how the massive layoffs will reshape the FDA and its impact on the drug and biologics industries.